HSK3486与丙泊酚用于成人全麻诱导的有效性比较:多中心、随机、双盲、对照、3期非劣效性试验
HSK3486组与丙泊酚组成功率分别为97.0%与97.6%,差异-0.57%(95%CI -5.4至4.2%),未跨越-8%非劣效界值;HSK3486注射痛发生率显著更低(18.0% vs 77.1%,P<0.0001)。
要点
- HSK3486全麻诱导成功率非劣效于丙泊酚。
- HSK3486注射痛发生率显著低于丙泊酚。
- 复合终点两组差异无统计学意义。
核心结论
- HSK3486在成功全麻诱导方面非劣效于丙泊酚,且注射痛显著更少。
主要发现
- HSK3486组与丙泊酚组全麻诱导成功率分别为97.0%与97.6%,差异-0.57%(95%CI -5.4至4.2%),未跨越-8%非劣效界值。
- HSK3486组注射痛发生率为18.0%(30例),丙泊酚组为77.1%(64例),P<0.0001。
- 排除注射痛后,与研究药物相关的治疗中出现的不良事件发生率HSK3486组为17.9%,丙泊酚组为14.5%。
关键数值与推荐
- 主要终点成功诱导定义为改良警觉/镇静评分≤1分。
- 非劣效界值为-8%。
- 关键次要终点包括注射痛(数字评定量表≥1分)比例及复合终点(成功诱导且维持目标麻醉深度且无显著心肺事件)。
临床怎么用
- HSK3486可作为丙泊酚的替代选择用于成人全麻诱导,尤其适用于关注注射痛的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Propofol is an intravenous anesthetic associated with hypotension, respiratory depression, and injection-site pain. HSK3486 injectable emulsion (ciprofol) is a 2,6-disubstituted phenol derivative with fast onset and quick, stable recovery. Previous studies support HSK3486 as an effective, safe anesthetic with substantially less injection-site pain than propofol. The primary objective of this study was to investigate the noninferiority of HSK3486 compared with propofol in successful general anesthesia induction. METHODS: Two hundred fifty-five participants were enrolled in HSK3486-304, a multicenter, randomized (2:1), double-blind, propofol-controlled, phase 3 study evaluating HSK3486 for general anesthesia induction in adults undergoing elective surgery with tracheal intubation. The primary endpoint was successful anesthesia induction, defined as 1 or less on the Modified Observer's Assessment of Alertness/Sedation scale. Key secondary endpoints were proportion of participants with injection-site pain on the Numerical Rating Scale of 1 or greater and a composite endpoint, including the proportion of participants successfully induced while maintaining the desired anesthetic depth and without substantial cardiac and respiratory events. Safety endpoints included adverse events, abnormal vital signs, and injection-site pain. RESULTS: Two hundred fifty-one participants (HSK3486, n = 168; propofol, n = 83) were included in the analyses. General anesthesia was successfully induced in 97.0% versus 97.6% of participants with HSK3486 and propofol, respectively. The difference in success rate was -0.57% (95% CI, -5.4 to 4.2%); the noninferiority boundary of -8% was not crossed. Thirty participants (18.0%) had injection-site pain with HSK3486 versus 64 (77.1%) with propofol (P < 0.0001). Eighty-one participants (48.2%) with HSK3486 versus 42 (50.6%) with propofol (P = 0.8780) satisfied the composite endpoint. When injection-site pain was excluded, the incidence of treatment-emergent adverse events related to study drug was 17.9% for HSK3486 and 14.5% for propofol. CONCLUSIONS: The study met its primary objective and endpoint, demonstrating noninferiority of HSK3486 compared with propofol in successful anesthetic induction. Substantially less injection-site pain was associated with HSK3486 than with propofol.
引用
- Gan TJ, Bertoch T, Habib AS, et al. Comparison of the Efficacy of HSK3486 and Propofol for Induction of General Anesthesia in Adults: A Multicenter, Randomized, Double-blind, Controlled, Phase 3 Noninferiority Trial. Anesthesiology. 2024. PMID: 38150544. doi:10.1097/ALN.0000000000004886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。